Canadian Cancer Trials Group Bulletins

Trial Management Group

Central Activation: MAC.22 TMIST Trial

MAC.22 Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

MAC.22 TMIST trial is the first randomized trial to compare two types of digital mammography for breast cancer screening, is now open for enrollment in Canada. The study was developed by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Health.

Patients must be women between the age 45 and 75 at the time of study entry. Women of childbearing potential must not be known to be pregnant or lactating Patients must be scheduled for, or have intent to schedule, a screening mammogram Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol. Written informed consent No symptoms or signs of benign or malignant breast disease No screening mammogram within the last 11 months prior to date of randomization No previous personal history of breast cancer including ductal carcinoma in situ No breast enhancements

To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of an advanced breast cancer at any time during a period of 4.5 years from randomization, including the period of active screening and a period of clinical follow-up after the last screen

For more information please contact CCTG Study Coordinator Wenling Liu